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Objectives:To determine the short- and long-term outcomes of patients treated operatively for Takayasu’s arteritis and the
effect of disease activity on results.
Methods: Forty-two (17%) of the 251 patients enrolled in our Takayasu’s arteritis registry between 1975 and 2002
required operation for symptomatic disease. Data were obtained from the registry, patient records, phone correspon-
dence, and written surveys.
Results:There were 38 females and 4 males with a median age of 29 years (range, 12 to 56 years), and 32 (76%) were white.
Sixty operations were performed for symptomatic disease. The mean duration of symptoms before operation was 5.6
months (range, 0 to 25 months). Thirteen (31%) patients had active disease and underwent operation for acute
presentation or failure of medical management. Thirty-nine patients (93%) had operation for occlusive disease.
Twenty-two (52%) patients had involvement of both the great and abdominal aortic branch vessels; 10 (24%) had great
vessel disease alone; 9 (21%) had involvement of abdominal arteries; and 1 (2%) had coronary artery disease. There was
no operative death, myocardial infarction, major stroke, or renal failure. Three patients had early graft thrombosis, two
had a minor stroke, and two developed hyperperfusion syndrome. The median follow-up was 6.7 years (range, 1 month
to 19.3 years). Eleven (26%) patients required 15 graft revisions; five of the patients had active disease at the time of initial
operation. All early revisions (<1 year) were in patients with active disease. By Kaplan-Meier analysis, freedom from
revision at 5 and 10 years was 100% in patients with quiescent disease not requiring steroids (group I, n  5, 12%), 95%
and 81% in patients whose disease was quiescent on steroids (group II, n  24, 57%), 57% in patients with active disease
on steroids (group III, n  7, 17%), and 33% in patients with active disease and no long-term steroids (group IV, n  6,
14%) (P< .006). The rate of revision or progression of disease at another site in 5 years was 0% in group 1, 10% in group
2, 57% in group 3, and 67% in group 4 (P< .001) The differences were even more pronounced when an analysis was done
on the basis of disease activity alone, irrespective of steroid use. During the follow-up period, 3 of 39 great vessel, 2 of 18
mesenteric/renal, and 1 of 9 aortofemoropopliteal reconstructions occluded. The predicted mortality for patients was 4%
at both 5 and 10 years (95% CI) respectively (confidence interval [CI], 0% to 11%) and 10 (CI, 0% to 14%) years,
respectively.
Conclusions: The minority of patients with Takayasu’s arteritis require operation. In our predominantly white female
patient population, occlusive symptoms were the most common indication for operation. Operation for these selected
patients was safe, with no operative mortality, myocardial infarction, major stroke, or renal failure. Patients with active
disease requiring operation are more likely to require revision or develop progressive symptomatic disease at another site.
Long-term survival is excellent, regardless of disease activity at the time of operation. (J Vasc Surg 2006;43:64-71.)Takayasu’s arteritis is a nonspecific inflammatory dis-
ease most famously described in 1908 by Mikito Takayasu,
an ophthalmologist in Japan.1 The inflammatory process
primarily affects large arteries such as the aorta and its
branches. The entity includes both occlusive and aneurys-
mal disease, the type of which varies by geographic loca-
tion. Occlusive disease is more prevalent in Japan, the
United States, and Europe, whereas aneurysmal disease is
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64more common in India, Thailand, Mexico, and Africa.2
The prevalence is higher in women, and the median age of
onset varies from 25 years in Asia and the United States to
41 years in Europe.3,4
If untreated, patients will die from cerebral hemor-
rhage, renal failure, heart failure, myocardial infarction,
cerebral thrombosis, or aneurysm rupture. To date, no
standard therapy is applicable to all patients. Most pa-
tients respond to medical therapy, but complications
from the disease may necessitate surgery in a poorly
documented minority of patients. Previous reports have
shown that operations can be performed safely. The
durability of the reconstructions has varied, however,
with some authors reporting a high incidence of reste-
nosis or pseudoaneurysm.4-12 Although clinicians have
long felt that disease activity affects outcomes, evidence-
based documentation of that effect on operation has
been lacking. In the absence of a uniform diagnosis of
disease activity, authors have often used steroid usage as
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ences between their patient subsets.
Further, few reports define the number of patients with
Takayasu’s arteritis needing repair. The purpose of this
study was to investigate the short- and long-term results of
patients treated operatively for Takayasu’s arteritis and the
effect of disease status on their outcomes.
PATIENTS AND METHODS
The clinic records of all patients with Takayasu’s arteri-
tis who required operation for symptomatic disease be-
tween January 1, 1975, and November 30, 2002, at the
Mayo Clinic in Rochester, Minn, were abstracted from a
Takayasu’s arteritis registry. Some of these patients have
been previously reported.8,12 Demographic data, comor-
bid medical conditions, history and physical findings, diag-
nostic and laboratory test results, operative records, pathol-
ogy reports, postoperative complications, graft patency,
and mortality were recorded. Complete follow-up was de-
fined as data obtained 12 months of the end point of the
study.
Diagnosis of Takayasu’s arteritis was made by using
American College of Rheumatology criteria, which com-
bines three or more clinical features or arteriographic find-
ings (Table I).13 All patients underwent thoracic and ab-
dominal aortography, with selected runoff views, to define
the location and extent of the disease. Pathologic criteria of
Takayasu’s arteritis included arterial wall infiltration by
lymphocytes, epithelioid cells, or giant cells; destruction of
medial elastic fibers, or replacement of medial smooth
muscle cells with fibrosis. Active disease was defined by two
or more of the following: clinical, pathologic, laboratory, or
operative criteria. These included systemic features such as
fevers, myalgias, or arthralgias; active inflammation on
pathologic specimen (eg, lymphoplasmacytic infiltrate, gi-
ant cells) taken from diseased arteries; elevation of serum
markers such as erythrocyte sedimentation rate (ESR) or
C-reactive protein; or acute inflammation of the artery and
Table I. The 1990 criteria for the classification of
Takayasu arteritis*
1. Development of symptoms or findings related to Takayasu
arteritis at age 40 years
2. Development and worsening of fatigue and discomfort in
muscles of one or more extremities while in use, especially the
upper extremities
3. Decreased pulsation of one or both brachial arteries
4. Difference of 10 mm Hg in systolic blood pressure between
arms
5. Bruit audible on auscultation over one or both subclavian
arteries or abdominal aorta
6. Arteriographic narrowing or occlusion of the entire aorta, its
primary branches, or large arteries in the proximal upper or
lower extremities, not due to arteriosclerosis, fibromuscular
dysplasia, or similar causes; changes usually focal or segmental
*For purposes of classification, a patient shall be said to have Takayasu
arteritis if at least three of these six criteria are present. The presence of any
three or more criteria yields a sensitivity of 90.5% and a specificity of 97.8%.surrounding soft tissues at the time of operation. Themainstay of medical management was corticosteroids (1
mg/kg), with the addition of other agents as dictated by
disease activity and clinical response to the steroids. Ste-
roids were continued for at least 3 months. A taper-in dose
was considered in patients who had clinical and laboratory
response to treatment.
Operations were done in patients who failed medical
therapy. This included those with acute symptoms with an
unrelenting clinical course or chronic symptoms despite
maximum medical therapy. All reconstructions or revisions
were done by open technique. No patient was treated with
angioplasty or stenting. All graft anastomoses were per-
formed to noninflamed areas of the target artery whenever
practicable. Graft patency was defined by the results of the
last imaging study, which included duplex ultrasonography
in 59%, arteriography in 23%, magnetic resonance imaging
(MRI) in 12%, and computed tomography (CT) in 6%. Ten
patients with aortoiliac reconstructions were assessed by
clinical examination alone and were not included in analysis
of patency.
Revision was defined as any operation performed to
maintain or re-establish patency of a vascular reconstruc-
tion. Early revision was defined as occurring1 year of the
initial operation. Progression of disease was defined as the
development of a symptomatic arterial stenosis or occlusion
in an area that previously had been uninvolved by arteriog-
raphy and that required another operative reconstruction.
Progression of disease was determined by a variety of diag-
nostic imaging, but primarily arteriography and MRA. Sur-
veillance intervals varied over the study. In the last 5 years of
the study, duplex scans were done within 3 to 6 months of
operation, 6 months later, and then annually thereafter.
Imaging was done for any patient with recurrent or new
symptoms.
Life-table analyses were done by the Kaplan-Meier
method to determine survival, freedom from revision, and
freedom from revision or progression of disease. These
outcomes were assessed by steroid use alone, by steroid use
and disease activity, and by disease activity alone, regardless
of steroid use.
We further subdivided the analysis into four groups:
group I included patients with quiescent disease no longer
on steroids; group II included patients with quiescent
disease on long-term steroids; group III was defined as
patients with active disease on steroids; and group IV were
those patients with acute active disease not previously on
steroids. A significant difference in outcome was denoted
by P  .05. The study was approved by the Institutional
Review Board of the Mayo Foundation.
RESULTS
Demographics, diagnosis, and operation. From January
1, 1975, to November 3, 2002, 42 (17%) of 251 patients in
our registry required 60 operations for symptomatic Taka-
yasu’s arteritis. Reconstructions were performed to 116
arteries. There were 38 females and 4 males with a median
age of 29 years (mean, 32; range, 12 to 56 years); 32 were
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(10%).
The clinical presentation is outlined in Table II. The
most common symptoms were either cerebrovascular or
exercise-induced limb ischemia; both symptom complexes
occurred in 16 patients each (38% for each group). Reno-
vascular hypertension or renal insufficiency occurred in 8
patients (19%); constitutional symptoms such as fever, mal-
aise, or fatigue occurred in 5 (9%); and cardiac symptoms
occurred in 3 (7%). Atherosclerotic risk factors included
hypertension (52%), smoking (38%), hyperlipidemia (14%),
and diabetes mellitus (7%).
Pathologic specimens were available in 35 of 42 pa-
tients undergoing operation. These were diagnostic of
Takayasu’s arteritis with giant cells and lymphocytic infil-
tration in 22 and the remaining 13 had pathology consis-
tent with Takayasu’s arteritis, with fibrosis and medial
degeneration. The ESR was also evaluated as a marker of
disease and had a sensitivity of 36% and specificity of 83%
compared with pathologic specimens. All 13 patients with
active disease were identified by pathologic specimens,
clinical factors, and surgical criteria. Nine of these had an
elevated ESR. Seven others with inactive disease were on
long-term steroid therapy and did not have pathology speci-
mens available for review. These patients were classified by
using clinical presentation, surgical criteria, and the ESR.
Preoperative cardiac testing included clinical history
and electrocardiography in 15 patients, dobutamine echo-
cardiography or sestamibi scans in 10 patients, cardiac
catheterization in 9, and echocardiography with electrocar-
diography in 8.
Occlusive disease occurred in 39 patients (93%). The
other three had aortic aneurysms (one infrarenal, one tho-
racic, and one ascending aorta). Twenty-two patients (52%)
had involvement of both the aortic arch and abdominal
aortic branch vessels; 10 (24%) had great vessel disease
alone; 9 (21%) had involvement of the abdominal arteries;
and 1 patient (4%) had coronary artery disease. One of the
Table II. Presenting signs and symptoms of patients
with Takayasu’s arteritis requiring operation
Sign or symptom* n %
Extremity Symptoms
Upper extremity exertional fatigue 1 19
Lower extremity claudication 5 9
Renal Symptoms
Hypertension 7 12
Renal failure 1 2
Neurologic
Dizziness 7 12
Visual disturbance 5 9
Global ischemia 5 9
Headache 3 5
Stroke 1 2
Systemic/constitutional symptoms 5 9
Congestive failure 3 5
*Some patients had more than one symptom or sign.patients with isolated great vessel disease also had pulmo-nary artery involvement. In addition, three patients had
aortic valve replacement at the time of reconstruction. Five
patients had reconstructions of the aorta or branch vessels
in different territories, all at the same operation (Fig 1).
Quiescent disease was present in 29 patients (69%).
Active disease was present in 13 patients (31%), of which six
not previously on steroid therapy presented with acute,
fulminant, life-threatening symptoms. Three had cre-
scendo transient ischemic attacks or global hypoperfusion,
two had congestive heart failure, and one had congestive
failure and acute renal failure. Intravenous steroid therapy
was initiated in all of these patients perioperatively.
Great vessel reconstructions were performed for pa-
tients with global hypoperfusion, transient ischemic attack,
or stroke. Ascending aorta and valve reconstructions were
performed for those with congestive heart failure, aneu-
rysm, or valve pathology. Renal reconstructions were per-
formed in patients with worsening renal function or hyper-
tension refractory to medical management. Aortoiliac
reconstructions were done in patients with incapacitating
claudication. Mesenteric reconstructions were performed
in symptomatic patients (abdominal pain, weight loss) or,
rarely, at the time of renal reconstruction in the few patients
who had critical disease in both beds.
Overall, the mean duration of symptoms before opera-
tion was 5.6 months (range, 0 to 25 months). The median
follow-up was 6.7 years (range, 1 month to 19.3 years).
Follow-up was complete in 79% of patients who lived
within the United States and in 71% of international
patients.
Early outcome. There were no operative or in-hospi-
tal deaths. No patient sustained a myocardial infarction,
major stroke, or renal failure. Fifteen major postoperative
complications occurred in 11 patients (Table III), of which
three had in-hospital carotid graft occlusions, and another
patient had a renal vein graft stenosis. All four grafts were
successfully revised. Two patients developed minor strokes.
One of the minor stroke patients was asymptomatic but had
a small area of infarction noted on a head CT scan. Two
other patients had cerebral hyperperfusion syndrome and
required intensive care but had no seizures or focal neuro-
logic deficits and had only small areas of intracranial hem-
orrhage. One of these also had abdominal compartment
syndrome. This problem developed in a young woman
whose great vessels, renal arteries, and entire thoracic ab-
dominal aorta were involved. A drawing of her reconstruc-
tion is shown in Fig 1. She had no non-reconstructed
vascular bed to compensate for the major hemodynamic
changes resultant from her operation. She required a large
amount of fluid intraoperatively. The four patients with
either minor stroke or hyperperfusion syndrome had full
recovery before hospital dismissal. Mean length of stay was
11 days, but varied by procedure.
Late outcome. Only one death occurred during fol-
low-up, and this was related to a motor vehicle accident.
The survival rate at 1 year was 100% and was 97% at both 5
and 10 years (Fig 2). There was no survival benefit related
to the use of steroids (Fig 3).
with
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dren by vaginal delivery after their operation for occlusive
disease. One patient has a small thoracic aneurysm that has
not required surgical repair. Two other patients with aneu-
rysms became pregnant but had elective abortions on the
Fig 1. Complex reconstruction performed in a patient w
disease. Arrows at areas of revascularization. (Reprinted
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Lymphocele 1recommendation of their referring physician before under-going repair. Twelve patients had great vessel involvement
alone, three had renal or mesenteric disease, and one had
great vessel and iliac involvement. Thirteen of 16 patients
were taking long-term steroids, and three had been recently
prescribed steroids at operation. The number of patients
ombined great vessel, thoracic aorta, and renal occlusive
permission of the Mayo Foundation.)
Fig 2. Observed survival among Takayasu’s arteritis patients re-
quiring operation compared with the expected survival of the
general United States white population based on census data.ith ctaking steroids at time of delivery was unknown, however.
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of disease. The graft patency in 32 patients (76%) was
confirmed by duplex ultrasound, MRI, CT, or arteriogra-
phy. All 42 patients had clinical evidence of patency that
included absence of symptoms, palpable pulses, equal ex-
tremity blood pressure measurement, normal ankle-brachial
indices, improvement or stability of renal function, and
absence of neurologic deficits.
Eleven patients (26%) required 15 graft revisions. Ten
were done 1 year, and the other five were done later. All
10 early revisions (1 year) and three of five late revisions
were in patients with active disease at the initial operation.
Three of 39 great vessel reconstructions, 2 of 18 mesenter-
ic/renal, and 1 of 9 aortofemoropopliteal reconstructions
occluded during the follow-up period.
Three patients (7%) had progressive disease requiring
operation at another arterial site. One had a mesenteric
reconstruction followed by an upper extremity reconstruc-
tion and subsequently an aortoiliac reconstruction. An-
other had a carotid reconstruction followed by a subclavian
reconstruction. The third patient had an aortic valve re-
placement with great vessel reconstruction followed by a
left renal bypass and then a right renal bypass.
Kaplan-Meier analysis was used to determine the effect of
steroid use, steroid use and disease activity, and activity alone
on the need for graft revision or progression of disease. When
all 42 patients were analyzed only by the presence or absence
of long-term steroid therapy, with no regard to disease activ-
ity, no differences in freedom from revision or disease progres-
sion were noted. However, when analyzed with respect to
steroid use and disease activity, there were significant differ-
ences (Figs 4 and 5). Freedom from revision at 5 and 10 years
was 100% in patients with quiescent disease not requiring
steroids (group I, n  5), 95% and 81% in patients whose
disease was quiescent on steroids (group II, n  24), 57% at
both 5 and 10 years in patients with active disease on steroids
(group III, n 7), and 33% at both 5 and 10 years in patients
with active disease not on long-term steroids (group IV, n
Fig 3. Freedom from revision based on the presence or absence
of steroid use at the time of operation.6) (P  .006) (Fig 6). The freedom from graft revision orprogression of disease at another site that required operation
was 100% in group I, 90% in group II, 43% in group III, and
33% in group IV (P  .001) (Fig 7). The differences were even
more pronounced when disease activity alone, irrespective of
steroid use, was used for the analysis (Figs 8 and 9).
DISCUSSION
Takayasu’s arteritis is a rare but potentially fatal disease
if left untreated. The disease is most common in Japan. In
the United States, it is estimated to occur in only 2.6 cases
per million people per year based on a population study
from Olmsted County, Minnesota.14 There is little in the
literature to tell us what percentage of patients with the
disease will require operation. The National Institutes of
Fig 4. Freedom from revision on the basis of steroid use and
disease activity. Group I vs group II (P  .49), I vs III (P  .14),
I vs IV (P .03), II vs III (P .045), II vs IV (P .0002), III vs
IV (P  .17)
Fig 5. Freedom from revision or progression on the basis of
steroid use and disease activity. Group I vs II (P  .40), I vs III
(P  .09), I vs IV (P  .03), II vs III (P  .02), II vs IV (P 
.0005), III vs IV (P  .29).Health reported operative interventions in 38% of 60 pa-
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higher because the patient cohort was selected only from
patients referred for vasculitis clinical trials and 25% of them
were lost to follow-up.4 Ishikawa et al15 operated on 12% of
their patients. Of the 251 patients entered in our registry,
which captures all patients at the Mayo Clinic with the
diagnosis of Takayasu’s arteritis, 17% needed operation.
Therefore, based on Ishikawa’s study and our own, we
believe that 20% of patients with Takayasu’s arteritis
require operation.
Most reports define patient outcome after operation by
early mortality and morbidity, survival, or graft-patency and
graft-related complications.5-7, 9-11 Operation for Takayasu’s
arteritis, even in multiple vascular territories, was safe in
these patients. Similar findings have been reported by
Weaver et al16for the treatment of patients with renovascu-
Fig 6. Freedom from revision on the basis of disease activity.
Fig 7. Freedom from revision or progression on the basis of
disease activity.lar disease. Operative mortality can certainly be affected bywhether the problem treated is occlusive or aneurysmal
disease. Robbs et al,7 from South Africa, reported an oper-
ative mortality of 3% to 4% in their patients with Takayasu’s
arteritis, most of whom had aneurysms. The mortality was
related to patients with ruptured aneurysms. A similar
mortality rate was noted by Kieffer et al17 for patients with
renovascular disease and Takayasu’s arteritis. In that series,
87% of the 24 patients operated on had combined aortic
and renal reconstruction and 71% had both renal and
mesenteric reconstruction. One patient (4%) died in the
immediate postoperative period from myocardial and intes-
tinal infarction. This patient had aortic, visceral, and renal
disease, but only the aortic and renal arteries were recon-
structed. We did not use endovascular techniques in the
patients in our series owing to the panmural involvement of
the artery in the disease process. Additionally, reports of
endovascular therapy for Takayasu’s are anecdotal.
The major complication rate in our series was low. No
patients had a major stroke, myocardial infarction, renal
failure, or pseudoaneurysm. The most common complica-
tions were cerebrovascular, and this reflects our patient
population, most of whom had great vessel disease, either
alone or with abdominal aortic branch vessel disease. For-
tunately, no patients had a major stroke, and the patients
with minor stroke recovered before hospital discharge.
Hyperperfusion syndrome, noted in two patients, is a risk
for patients with extensive great vessel involvement. In four
patients, early graft occlusions occurred during a time when
we were not routinely using intraoperative duplex scans to
access the technical outcome of the reconstruction.
Another important outcome in our study was the safety
of pregnancy in women of childbearing age. Female pa-
tients frequently ask about the safety of pregnancy. Tradi-
tional teaching has suggested that these patients may have a
higher risk of complications during the gestational period
that can affect both the mother and fetus. Two patients in
our series with aneurysmal disease became pregnant but
had elective abortions on the recommendation of their
local physician before referral to our institution. Sixteen
other patients had safe vaginal deliveries after their opera-
tions for occlusive disease. One of these patients had a small
thoracic aneurysm that has not been treated to date. In
contrast, a study from India showed that among 24 preg-
nant women with Takayasu’s arteritis, there were five intra-
uterine fetal deaths and two abortions. The mothers did not
seek prenatal or perinatal care until late in the pregnancy.18
The most significant findings from our study were the
impact of disease activity on survival, the need for graft
revision, and the progression of disease at a remote site.
Our long-term survival is excellent up to 10 years and was
not affected by disease activity or the use of steroids. Similar
survival was noted by Weaver et al.16
Complex analyses have been reported by the Japanese
in an effort to predict long-term prognosis. Ishikawa et al15
proposed a cumbersome staging system based on a modi-
fication of the Akaike information criterion. We did not use
this staging system in our study because of its unwieldy
nature and because few of our patients had retinopathy,
JOURNAL OF VASCULAR SURGERY
January 200670 Fields et alaortic valve regurgitation, or arterial aneurysms; therefore,
it was not useful for our analysis. We found serum markers
of less value than operative findings, clinical presentation,
course of disease, and arteriographic findings. There was
also poor correlation between serum markers in our pa-
tients and their pathologic findings. With erythrocyte sed-
imentation rate specifically, the sensitivity of the test was
36% and specificity 83% based on comparison with the
pathologic specimen.
It may be argued that our 10-year length of follow-up is
too short to determine the mortality rate. Miyata et al5 re-
ported 12 hospital deaths and an additional 31 late deaths in a
series of 106 patients treated operatively for Takayasu’s dis-
ease. Their mean follow-up was 19.8 years, and the mean
survival rate at 20 years was 73.5%. The most common
cause of death in that series was congestive heart failure.
These authors believe that long-term follow-up of 20
years is mandatory to make any statistical conclusions about
the impact of surgical therapy on the natural history of
disease. In contrast to our patients, anastomotic aneurysms
were found in 13.8% of their patients at the 20-year follow-
up.5 No false aneurysms occurred in our series, and we
believe that the incidence of false aneurysms can be reduced
by constructing anastomoses beyond inflamed areas.
It has been a clinical impression for years that the results
of operation are impacted by disease activity at the time of
surgery. We have been able to provide clinical evidence of
this by grouping our patients with respect to both their
medication needs and clinical status.
Other authors have relied on steroid use as the sole
determinant of disease activity. We found no difference in
the rate of graft revision or on progression of symptomatic
disease at another site when we analyzed our patients in this
fashion (Fig 3). To equate steroid use alone as a marker of
disease activity in these patients is inherently inaccurate. For
example, our “best risk” patients —those with quiescent
disease no longer requiring steroids—would be lumped
with our “worst” patients—those who had active disease
presenting acutely and not yet on steroids. Similarly, the
groups of patients with active or quiescent disease on
steroids would have been analyzed as a single cohort.
Our best outcomes, when analyzed according to the
need for graft revision, occurred in patients with quiescent
disease on no steroids. Freedom from graft revision at 5 and
10 years was 100% in this group. Those who had quiescent
disease on steroids had a slightly worse outcome, with
freedom from graft revision 95% at 5 years and 81% at 10
years. The worst outcomes were noted in patients with
active disease, especially those with acute presentations not
previously on glucocorticoid therapy (Figs 4-7).
Finally, when we analyzed the rate of graft revision or
progression of disease based on activity alone, irrespective
of steroid use, the differences in graft revision or progres-
sion of disease were even more pronounced. Patients with
active disease did significantly worse than those with quies-
cent disease. Some have argued that most patients have an
initial insult from the disease and they have little chance oflate symptomatic recurrence, but our findings dispute that
supposition.16
The interpretation of our results may have several lim-
itations:
First, the operations were done over a long period of time,
during which medical treatment changed and the rou-
tine use of imaging studies for assessment of graft
patency varied.
Second, the definition of active vs quiescent disease is
difficult and not uniform in the current literature. Our
definition of active disease, however, was very stringent
and included a combination of clinical, pathologic, or
laboratory findings. We believe this definition provides
a better assessment of the acuity of illness than the
American College of Rheumatology criteria used to
define active disease.13 Our patients with active disease
had to have two or more of the following: systemic
symptoms, evidence of acute inflammation in the target
artery and surrounding tissues, pathologic evidence of
active inflammation in the arterial wall, or elevated
serum markers.
Third, follow-up was complete in approximately 80% of our
patients who resided in the United States. Although
this represented most of our group, it is possible that
we did not capture some asymptomatic graft stenoses
or occlusions, which could skew the results in our
analysis. The follow-up in our study is similar to that
reported recently by Weaver et al,16 but it is not as long
as that reported in the Japanese literature.5,15 It is
possible that longer follow-up would have uncovered
other late graft-related problems such as false aneu-
rysms. Additionally, since Takayasu’s arteritis is rare
and the experience at any single center is limited, it is
difficult to accumulate larger numbers of patients in a
short time frame to increase the predictive value of our
life-table analyses.
Finally, the results of our study may primarily be applicable
to patients with occlusive disease, which represented
93% of our group.
CONCLUSION
Few patients with Takayasu’s arteritis require opera-
tion. In our predominantly white female population, occlu-
sive symptoms were the most common indication for op-
eration. Operations for these problems can be performed
safely in selected patients. Long-term survival is excellent,
regardless of disease activity at the time of operation. How-
ever, disease activity significantly increased the likelihood of
graft revision or the progression of symptomatic disease at
another site. These findings support the need for long-term
monitoring of vascular reconstructions in patients with
Takayasu’s arteritis, especially in patients with active disease
at the time of initial operation.
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Dr Lars Svensson (Cleveland, Ohio). Dr White, Dr Ouriel,
ladies and gentlemen: I congratulate Dr Fields and his Mayo Clinic
colleagues on an excellent study and well-written manuscript on a
27-year experience. Our experience has been similar at the Cleve-
land Clinic with 105 patients followed by my colleague, Dr Gary
Hoffman; however, 50 have undergone surgery, which perhaps, is
a reflection of our referral patterns.
I have three questions about the diagnosis, medical therapy, and
bypass graft types you used. You refer to the 1990 preoperative criteria
for the diagnosis in your manuscript and your table. Do you not think
that these are too liberal? Any patient with a subclavian or innominate
artery stenosis could technically qualify, making it hard to differentiate
former TB patients, young female heavy smokers, or as we have seen
in about a half a dozen patients, patients with silicone breast prosthe-
ses. TB may account for the increased diagnosis of Takayasu’s type
aneurysms in the countries of Africa, India, and Russia.
You divided patients partly by steroid use, but how did you
categorize patients who were on and off steroids? Did you use
C-reactive protein levels for both treatment, timing of surgery and
prognostication? It appears that patients with CRP levels below 1
mg/dL have an excellent long-term outcome, but those with 1 mg
or higher had frequent events and close long-term follow-up is
required in these patients.
We learned in the 1980s that saphenous vein grafts were
unsuitable for bypasses and that Dacron polyester grafts were
preferable in these types of patients. Can you comment on your
experience, what you currently use for grafts, and how many of
your patients that failed had saphenous vein bypasses?
I thank the Society for the invitation to comment on this
excellent study.
Dr Charles Fields. To address the first point, the American
College of Rheumatology criteria for diagnosis of Takayasu’s dis-
ease are basically clinical criteria, which inherently, as Dr Svensson
has suggested, can miscategorize patients. However, we accounted
for this by also looking at the pathologic slides of these patientsinclude review of pathology as part of the criteria, we feel that
patients with three of the six symptoms described by the ACR
criteria, as well as findings on pathology, definitely had Takayasu’s
arteritis.
In reference to patients with tuberculosis or with silicone
breast implants or other possibly etiologies of Takayasu’s arteritis,
we agree wholeheartedly that the Takayasu’s arteritis that is seen in
places such as India or South Africa may be of a different variant,
since these patients tend to have aneurysmal disease. We did not
have any patients in our series that had had silicone breast implants,
and we only had two patients that had had a history of positive PPD
in the past. So these are excellent points.
As far as patients who had been on or off steroids during the
course of our review, we have basically clinical medical manage-
ment criteria that we use at Mayo Clinic that consist primarily of
corticosteroid use as first-line therapy. This is usually dosed at 1
mg/kg for all of these patients, and then we taper the steroid dose
accordingly as the symptoms subside. We did not have any patients
in this series that were classified originally as the on-steroid group
that were able to come off steroids at some point during the study
period. However, we did have patients that weren’t on steroids
initially in our active disease group, and they received pulses of
steroids at the time of operation. So we did try to give them some
steroid coverage, but it wasn’t as chronic as the other active or
chronic disease patients.
As far as measuring the levels of C-reactive protein, we actually
did a sensitivity and specificity analysis of sed rate compared to our
pathologic specimens. And as several authors have found, the data
was not very good as far as using serum markers for a determinant
of disease. However, as far as C-reactive protein is concerned, only
a minority of our patients had that level measured, as we tend to
use sed rate as our marker.
And finally, as far as type of graft, we had one patient who had
had aortorenal grafts constructed with saphenous vein, which later
became aneurysmal. Most of the other patients in this series had
Dacron graft reconstructions.
